Advances in temporizing treatment strategies and associated complications for posthemorrhagic hydrocephalus in preterm infants.

Facing life-threatening end-stage heart failure and cardiogenic shock, the treatment of pediatric patients heavily relies on cardiac assist devices, such as Intra-aortic Balloon Pump(IABP), Extracorporeal Membrane Oxygenation (ECMO), and Ventricular Assist Device (VAD). These devices can partially or completely replace the heart’s pumping function, maintain systemic circulation, reduce cardiac load, and improve myocardial oxygen supply, providing life support for children []. However, the rapidly changing anatomical structures, developing nervous system, and coagulation function in children make device adaptation complex. Direct application of adult devices and techniques presents significant adaptation challenges and directly leads to unique and higher risks of complications. The core regulatory conflict in pediatric cardiology stems from the disparity between the clinical need for cardiovascular devices in children and the high risk of complications: the gap between children’s urgent need for safe and effective treatment devices and the insufficient support from the existing regulatory evidence system. This conflict obscures the true risk profile of the pediatric population. This has led to a long-standing, vague, and potentially underestimated understanding of the safety of pediatric cardiac assist devices [,]. Therefore, systematically revealing the true differences in adverse events between pediatric and adult patients, scientifically evaluating the limitations of existing regulatory databases, and revealing the risk lag of the existing detection standards by combining real-world data become the empirical basis for promoting precise regulation of pediatric medical devices. This study, based on the FDA MAUDE database, focuses on three types of devices: IABP, VAD, and ECMO. By systematically analyzing pediatric adverse event data and comparing their main complications with adult data, this research aims to quantify the risk differences and empirically assess the effectiveness and shortcomings of traditional regulatory data in pediatric applications. This will provide crucial evidence for building a life-cycle regulatory framework for pediatric medical devices based on real-world evidence.